No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker AstraZeneca said on Wednesday that its Imfinzi asset has been approved in the US for use alongside standard FLOT chemotherapy in the treatment of adult patients with resectable, earlystage and locally advanced gastric and gastroesophageal junction cancers.
AstraZeneca said the regimen covers neoadjuvant Imfinzi with chemotherapy ahead of surgery, followed by adjuvant Imfinzi with chemotherapy and then Imfinzi monotherapy.
The FTSE 100-listed firm stated approval from the Food and Drug Administration followed a Priority Review and was based on eventfree and overall survival data from its Phase III MATTERHORN trial.
Dave Fredrickson, executive vice president of AstraZeneca's oncology haematology business unit, said: "This approval ushers in a new clinical paradigm for patients with early gastric and gastroesophageal junction cancers, with Imfinzi plus FLOT delivering a durable survival benefit that increases over time.
"As the third US approval for a perioperative Imfinzi-based regimen, this milestone further validates the perioperative approach and underscores our focus on bringing novel treatments to early-stage cancers where cure is the goal."
Reporting by Iain Gilbert at Sharecast.com
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.